Himanshi Singh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Himanshi Singh has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Mohammad Moshahid Khan
Department of Neurology, College of Medicine, University of Tennessee Health Science Center, Memphis, USA
3 shared publications - Dhruvil Solanki
Department of Physics and Astronomy, Mississippi State University, Mississippi State, MS 39762, USA
2 shared publications - Ishmael Apachigawo
Department of Physics and Astronomy, Mississippi State University, Mississippi State, MS 39762, USA
2 shared publications - Prabhakar Pradhan
Department of Physics and Astronomy, Mississippi State University, Mississippi State, MS 39762, USA
2 shared publications - Sazzad Khan
Department of Neurology, College of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA
2 shared publications Asmita Das
Delhi Technological University, Memphis, TN USA
1 shared publication
Latest Publications
- Open Access
- 20 June 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (7) , 907
DNA Damage Response Regulation Alleviates Neuroinflammation in a Mouse Model of α-Synucleinopathy
Parkinson’s disease (PD) is a progressive neurodegenerative disorder marked by the degeneration of dopaminergic neurons in the substantia nigra, leading to decreased dopamine levels in the striatum and causing a range of motor and non-motor impairments. Although the molecular mechanisms driving PD progression remain incompletely understood, emerging evidence suggests that the buildup of nuclear DNA damage, especially DNA double-strand breaks (DDSBs), plays a key role in contributing neurodegeneration, promoting senescence and neuroinflammation. Despite the pathogenic role for DDSB in neurodegenerative disease, targeting DNA repair mechanisms in PD is largely unexplored as a therapeutic approach. Ataxia telangiectasia mutated (ATM), a key kinase in the DNA damage response (DDR), plays a crucial role in neurodegeneration. In this study, we evaluated the therapeutic potential of AZD1390, a highly selective and brain-penetrant ATM inhibitor, in reducing neuroinflammation and improving behavioral outcomes in a mouse model of α-synucleinopathy. Four-month-old C57BL/6J mice were unilaterally injected with either an empty AAV1/2 vector (control) or AAV1/2 expressing human A53T α-synuclein to the substantia nigra, followed by daily AZD1390 treatment for six weeks. In AZD1390-treated α-synuclein mice, we observed a significant reduction in the protein level of γ-H2AX, a DDSB marker, along with downregulation of senescence-associated markers, such as p53, Cdkn1a, and NF-κB, suggesting improved genomic integrity and attenuation of cellular senescence, indicating enhanced genomic stability and reduced cellular aging. AZD1390 also significantly dampened neuroinflammatory responses, evidenced by decreased expression of key pro-inflammatory cytokines and chemokines. Interestingly, mice treated with AZD1390 showed significant improvements in behavioral asymmetry and motor deficits, indicating functional recovery. Overall, these results suggest that targeting the DDR via ATM inhibition reduces genotoxic stress, suppresses neuroinflammation, and improves behavioral outcomes in a mouse model of α-synucleinopathy. These findings underscore the therapeutic potential of DDR modulation in PD and related synucleinopathy.
- 20 June 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (7) , 907
Open AccessDNA Damage Response Regulation Alleviates Neuroinflammation in a Mouse Model of α-Synucleinopathy
Parkinson’s disease (PD) is a progressive neurodegenerative disorder marked by the degeneration of dopaminergic neurons in the substantia nigra, leading to decreased dopamine levels in the striatum and causing a range of motor and non-motor impairments. Although the molecular mechanisms driving PD progression remain incompletely understood, emerging evidence suggests that the buildup of nuclear DNA damage, especially DNA double-strand breaks (DDSBs), plays a key role in contributing neurodegeneration, promoting senescence and neuroinflammation. Despite the pathogenic role for DDSB in neurodegenerative disease, targeting DNA repair mechanisms in PD is largely unexplored as a therapeutic approach. Ataxia telangiectasia mutated (ATM), a key kinase in the DNA damage response (DDR), plays a crucial role in neurodegeneration. In this study, we evaluated the therapeutic potential of AZD1390, a highly selective and brain-penetrant ATM inhibitor, in reducing neuroinflammation and improving behavioral outcomes in a mouse model of α-synucleinopathy. Four-month-old C57BL/6J mice were unilaterally injected with either an empty AAV1/2 vector (control) or AAV1/2 expressing human A53T α-synuclein to the substantia nigra, followed by daily AZD1390 treatment for six weeks. In AZD1390-treated α-synuclein mice, we observed a significant reduction in the protein level of γ-H2AX, a DDSB marker, along with downregulation of senescence-associated markers, such as p53, Cdkn1a, and NF-κB, suggesting improved genomic integrity and attenuation of cellular senescence, indicating enhanced genomic stability and reduced cellular aging. AZD1390 also significantly dampened neuroinflammatory responses, evidenced by decreased expression of key pro-inflammatory cytokines and chemokines. Interestingly, mice treated with AZD1390 showed significant improvements in behavioral asymmetry and motor deficits, indicating functional recovery. Overall, these results suggest that targeting the DDR via ATM inhibition reduces genotoxic stress, suppresses neuroinflammation, and improves behavioral outcomes in a mouse model of α-synucleinopathy. These findings underscore the therapeutic potential of DDR modulation in PD and related synucleinopathy.
- Open Access
- 1 December 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (S1) , e093509
Persistent DNA damage response drives cGAS‐STING mediated neuroinflammation in a mouse model of tauopathy
Background: Tauopathies are a group of neurological disorders including Alzheimer’s disease that involve progressive neurodegeneration, behavioral deficits, and aberrant tau accumulation. While the molecular mechanisms that regulate the progression of the tauopathy are not fully elucidated, there is evidence to suggest that accumulation of nuclear DNA damage, particularly nuclear DNA double‐strand breaks (DNA DSBs), contribute to the progression of neurodegeneration. In our present work, we investigated the relationship between DNA DSB accumulation and neuroinflammation in the brains of AD patients and a mouse model of tauopathy.Method: We used multiple approaches including ELISA, RT‐qPCR, Western blot and immunohistochemistry to examine the DNA DSB expression and DNA repair function in the entorhinal cortex of human AD and non‐AD brains.Result: In comparison to non‐AD subjects, we found increased g‐H2A.X (Ser139) a biomarker of DNA DSB and reduced expression levels of DNA repair proteins in the entorhinal cortex of human AD brains. This was positively correlated with upregulation of cyclic GMP‐AMP synthase (cGAS) and stimulator of interferon genes (STING) immune regulatory pathway, and tau pathology. Next, we observed higher amounts of DNA DSB and altered expression levels of DNA repair proteins in the brains of PS19Tg mice as compared to non‐Tg mice. Our results showed that increased DNA DSBs and reduced expression of DNA repair proteins were further associated with significant increase in cGAS‐STING pathway.Conclusion: These results offered strong evidence that tauopathy is linked to DNA DSB accumulation and/or changes in DNA repair proteins, which may have an impact on a critical initial step of the process, such as neuroinflammation, leading to neurodegeneration and memory loss.
- 1 December 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (S1) , e093509
Open AccessPersistent DNA damage response drives cGAS‐STING mediated neuroinflammation in a mouse model of tauopathy
Background: Tauopathies are a group of neurological disorders including Alzheimer’s disease that involve progressive neurodegeneration, behavioral deficits, and aberrant tau accumulation. While the molecular mechanisms that regulate the progression of the tauopathy are not fully elucidated, there is evidence to suggest that accumulation of nuclear DNA damage, particularly nuclear DNA double‐strand breaks (DNA DSBs), contribute to the progression of neurodegeneration. In our present work, we investigated the relationship between DNA DSB accumulation and neuroinflammation in the brains of AD patients and a mouse model of tauopathy.Method: We used multiple approaches including ELISA, RT‐qPCR, Western blot and immunohistochemistry to examine the DNA DSB expression and DNA repair function in the entorhinal cortex of human AD and non‐AD brains.Result: In comparison to non‐AD subjects, we found increased g‐H2A.X (Ser139) a biomarker of DNA DSB and reduced expression levels of DNA repair proteins in the entorhinal cortex of human AD brains. This was positively correlated with upregulation of cyclic GMP‐AMP synthase (cGAS) and stimulator of interferon genes (STING) immune regulatory pathway, and tau pathology. Next, we observed higher amounts of DNA DSB and altered expression levels of DNA repair proteins in the brains of PS19Tg mice as compared to non‐Tg mice. Our results showed that increased DNA DSBs and reduced expression of DNA repair proteins were further associated with significant increase in cGAS‐STING pathway.Conclusion: These results offered strong evidence that tauopathy is linked to DNA DSB accumulation and/or changes in DNA repair proteins, which may have an impact on a critical initial step of the process, such as neuroinflammation, leading to neurodegeneration and memory loss.
- Open Access
- 14 November 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (22) , 12211
Dual Photonics Probing of Nano- to Submicron-Scale Structural Alterations in Human Brain Tissues/Cells and Chromatin/DNA with the Progression of Alzheimer’s Disease
Understanding alterations in structural disorders in tissue/cells/building blocks, such as DNA/chromatin in the human brain, at the nano to submicron level provides us with efficient biomarkers for Alzheimer’s detection. Here, we report a dual photonics technique to detect nano- to submicron-scale alterations in brain tissues/cells and DNA/chromatin due to the early to late progression of Alzheimer’s disease in humans. Using a recently developed mesoscopic light transport technique, fine-focused nano-sensitive partial wave spectroscopy (PWS), we measure the degree of structural disorder in tissues. Furthermore, the chemical-specific inverse participation ratio technique (IPR) was used to measure the DNA/chromatin structural alterations. The results of the PWS and IPR experiments showed a significant increase in the degree of structural disorder at the nano to submicron scale at different stages of AD relative to their controls for both the tissue/cell and DNA cellular levels. The increase in the structural disorder in cells/tissues and DNA/chromatin in the nuclei can be attributed to higher mass density fluctuations in the tissue and DNA/chromatin damage in the nuclei caused by the rearrangements of macromolecules due to the deposition of the amyloid beta protein and damage in DNA/chromatin with the progress of AD.
- 14 November 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (22) , 12211
Open AccessDual Photonics Probing of Nano- to Submicron-Scale Structural Alterations in Human Brain Tissues/Cells and Chromatin/DNA with the Progression of Alzheimer’s Disease
Understanding alterations in structural disorders in tissue/cells/building blocks, such as DNA/chromatin in the human brain, at the nano to submicron level provides us with efficient biomarkers for Alzheimer’s detection. Here, we report a dual photonics technique to detect nano- to submicron-scale alterations in brain tissues/cells and DNA/chromatin due to the early to late progression of Alzheimer’s disease in humans. Using a recently developed mesoscopic light transport technique, fine-focused nano-sensitive partial wave spectroscopy (PWS), we measure the degree of structural disorder in tissues. Furthermore, the chemical-specific inverse participation ratio technique (IPR) was used to measure the DNA/chromatin structural alterations. The results of the PWS and IPR experiments showed a significant increase in the degree of structural disorder at the nano to submicron scale at different stages of AD relative to their controls for both the tissue/cell and DNA cellular levels. The increase in the structural disorder in cells/tissues and DNA/chromatin in the nuclei can be attributed to higher mass density fluctuations in the tissue and DNA/chromatin damage in the nuclei caused by the rearrangements of macromolecules due to the deposition of the amyloid beta protein and damage in DNA/chromatin with the progress of AD.
- Open Access
- 26 October 2023
- Published by MDPI AG in Biophysica
- Vol. 3 (4) , 569-581
Fractal Dimension Analyses to Detect Alzheimer’s and Parkinson’s Diseases Using Their Thin Brain Tissue Samples via Transmission Optical Microscopy
Biological tissues in nature are fractal due to their self-similarity and porosity properties. These properties change with the progress of some diseases, including brain tissue in leading neurological disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). Thus, there is an unmet clinical need to develop a tool for accurate and early diagnosis of AD and PD conditions. Although the whole brain tissues in AD and PD have been extensively studied, their local structural alterations at the nano-to-submicron levels have not been explored. In this paper, we measure the local structural alterations in different brain regions of AD and PD patients by measuring their change in fractal dimensions via optical microscopy. Our results show an increase in the fractal dimension value of ~5–10% in the affected regions of the brain tissues relative to their respective controls. For AD cases, the structural alteration is attributed to the aberrant deposition of amyloid beta protein and neurofibrillary tangles in the brain, and for PD, the gradual loss of dopaminergic neurons and abnormal accumulation of α-synuclein in the brain. The work will enhance the further understanding of alterations in the brain structures in AD and PD and its detection.
- 26 October 2023
- Published by MDPI AG in Biophysica
- Vol. 3 (4) , 569-581
Open AccessFractal Dimension Analyses to Detect Alzheimer’s and Parkinson’s Diseases Using Their Thin Brain Tissue Samples via Transmission Optical Microscopy
Biological tissues in nature are fractal due to their self-similarity and porosity properties. These properties change with the progress of some diseases, including brain tissue in leading neurological disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). Thus, there is an unmet clinical need to develop a tool for accurate and early diagnosis of AD and PD conditions. Although the whole brain tissues in AD and PD have been extensively studied, their local structural alterations at the nano-to-submicron levels have not been explored. In this paper, we measure the local structural alterations in different brain regions of AD and PD patients by measuring their change in fractal dimensions via optical microscopy. Our results show an increase in the fractal dimension value of ~5–10% in the affected regions of the brain tissues relative to their respective controls. For AD cases, the structural alteration is attributed to the aberrant deposition of amyloid beta protein and neurofibrillary tangles in the brain, and for PD, the gradual loss of dopaminergic neurons and abnormal accumulation of α-synuclein in the brain. The work will enhance the further understanding of alterations in the brain structures in AD and PD and its detection.